enVVeno Medical Receives FDA Approval for Venous Valve Study

enVVeno Medical Corporation has announced that the FDA approved its Investigational Device Exemption (IDE) application. This approval permits the company to initiate a pivotal study for its Transcatheter Venous Valve Endoprosthesis (TAVVE®), a non-surgical replacement venous valve. The company also reported sufficient cash and investments, approximately $25 million, to fund operations into the third quarter of 2027.